Pulse Biosciences appoints Gansevoort Dunnington, M.D CMO

Pulse Biosciences announced the appointment of Gansevoort "Gan" Dunnington, M.D. as its Chief Medical Officer. "On behalf of the Company, I am thrilled to welcome Dr. Dunnington to the Pulse Biosciences team," said Kevin Danahy, Chief Executive Officer of Pulse Biosciences. "Dr. Dunnington brings a wealth of knowledge, expertise, and experience in the field of cardiothoracic surgery, where he is a leader in pioneering novel less-invasive technologies that improve the lives of patients with atrial fibrillation. We look forward to his leadership and contributions, as we continue to harness the power of nanosecond pulsed field ablation to have a significant and meaningful positive impact on the treatment outcomes of atrial fibrillation, all the while being increasingly patient and physician friendly."